This website uses cookies to ensure that we give you the best user experience. If you choose to continue using this website, you agree to our use of cookies. Ok, got it!
Contact us today to see how we can help
Contact Us
P. McEwan, M. Hurst, L. Hoskin, K. Badora, D. Sugrue, G. James, E. Tafesse. PDB59 the impact of hyperkalaemia and its concurrence with cardiorenal comorbidities on healthcare resource use in the UK. Value in Health 2020; 23 (suppl 1): S119.
Ryan A, Sugrue D, Hurst M, Thakkar P, Hartridge-Lambert S, Kayhanian H, Gordon J, Rodriguez-Justo M, Shiu KK, Ntais D. Time on treatment and treatment patterns in patients with metastatic colorectal carcinoma: a retrospective chart review. Poster presented at: NCRI Cancer Conference; 2019 Nov 3-5; Glasgow, UK.
Gordon J, Beresford-Hulme L, Bennett H, Tank A, Edmonds C, McEwan P. PDB96 THE IMPACT OF ADJUNCT DAPAGLIFLOZIN ON TREATMENT SATISFACTION IN TYPE 1 DIABETES MELLITUS. Value in Health. 2019 Nov 1;22:S590.
Hill N, Lister S, Sandler B, Farooqui U, Mokgokong R, Sugrue D, Ward T, Boyce R, Gordon J. PCV50 COST-EFFECTIVENESS OF TARGETED SCREENING USING A MACHINE LEARNING RISK PREDICTION TOOL FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION. Value in Health. 2019 Nov 1;22:S550.
Ward T, Parker B, Hayward O, Jacob I, McEwan P, Becker DL, Arthurs E, Anderson SJ, Chounta V, Van de Velde N. PIN15 THE VALUE OF ACHIEVING OPTIMAL ADHERENCE WITH LONG-ACTING DIRECTLY OBSERVED ANTIRETROVIRAL THERAPY (LA DOT ART) AMONGST PATIENTS LIVING WITH HIV-1 INFECTION: A MODELLING STUDY. Value in Health. 2019 Nov 1;22:S642.
McEwan P, Bennett H, Kartman B, Edmonds C, Gause-Nilsson I, Wilding J. PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?. Value in Health. 2019 Nov 1;22:S581.
Sugrue D, Van Haalen H, Garcia Sanchez JJ, Darlington O, Mcewan P. FP370 THE RELATIONSHIP BETWEEN RENAL FUNCTION AND OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW. Nephrology Dialysis Transplantation. 2019 Jun 1;34(Supplement_1):gfz106-FP370.
Mcewan P, FOOS V, Bennett H, Kartman B, Edmonds C, Gause-Nilsson IA. 1269-P: Assessing the Performance of the UKPDS 82 Risk Equations to Predict Cardiovascular Events in the DECLARE-TIMI 58 Trial Population.
Mcewan P, FOOS V, Bennett H, Kartman B, Edmonds C, Gause-Nilsson IA. 1213-P: Assessing the Performance of Cardiovascular Risk Equations in the DECLARE-TIMI 58 Population.
McEwan P, Kartman B, Bennett H, Edmonds C, Gause-Nilsson IA. 15-OR: Renal Outcomes from the DECLARE-TIMI 58 Trial: Quantifying the Health-Care Implications.
Kartman BB, Mcewan P, Bennett H, Edmonds C, Gause-Nilsson I. Hospitalisation for heart failure: short term cost savings associated with outcomes reported from the DECLARE-TIMI 58 trial. InEUROPEAN JOURNAL OF HEART FAILURE 2019 May 1 (Vol. 21, pp. 218-219). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
Lopes S, Anderson SJ, Oglesby A, Jacob I, McEwan P, Ward T. PIN31 DOLUTEGRAVIR PLUS LAMIVUDINE FOR THE TREATMENT OF ART NAIVE ADULTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A US COST-UTILITY ANALYSIS. Value in Health. 2019 May 1;22:S199.
Oglesby A, Nguyen C, Jacob I, Anderson SJ, McEwan P, Lopes S, Ward T. PIN29 ESTIMATION OF THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A TEST AND TREAT (T&T) ANTIRETROVIRAL (ARV) REGIMEN FOR TREATMENT-NAIVE PATIENTS WITH HIV-1 INFECTION IN THE UNITED STATES. Value in Health. 2019 May 1;22:S198-9.
Darlington O, Palaka E, McEwan P, Bergenheim K, Bennett H, Grandy S. Use of a Lifetime Stimulation Model to Quantify the Impact of Hyperkalaemia on Predicted and Quality-adjusted Life Expectancy in Patients with Heart Failure or Chronic Kidney Disease
Palaka E, Darlington O, McEwan P, Qin L, Bennett H, Grandy S. Estimating the Clinical and Economic Burden of Additional Hospitalisation Associated with Hyperkalaemia and Raasi Therapy Management : A Modelling Study in Patients With Chronic Kidney Disease or Heart Failure
Darlington O, McEwan P, Palaka E, Grandy S, Qin L. Estimating the Clinical and Economic Burden of Hyperkalaemia in Patients With Chronic Kidney Disease or Heart Failure.
Ward T, Punekar YS, Darlington O, McEwan P, Martin A, Urbaityte R, Lopes S. Dolutegravir Plus Lamivudine for the Treatment of Naive Adults Living with HIV-1: A UK Cost-minimization Analysis
Ward T, Bennett H, McEwan P, Edmonds C, Kartman B, Fenici P, Thuresson M, Kosiborod M. The Health Economic Value of Short-term Cardiovascular Benefits Associated with SGLT-2i from CVD-REAL
Ward T, Sugrue D, McEwan P, Cunningham T, van Haalen H. Validation and Conceptual Design of a Health Economic Model for Anaemia in Myelodysplastic Syndrome
Linde C, McEwan P, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Grandy S, Palaka E, Qin L. Real-world Dosing of Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure Patients, and Associations Between Hyperkalaemia and Down-Titration or Discontinuation
Qin L, McEwan P, Ayoubkhani D, Reeve L, Grandy S, Palaka E, Evans M. The Association Between Renin-Angiotensin-Aldosterone System Inhibitors Dose Reduction and Risk of Mortality and Major Adverse Cardiovascular Events in Heart Failure Patients
Sugrue D, Hayes A, McNamara B, McEwan P, Cunningham T, van Haalen HG. A Health Economic Model for Myelodysplastic Syndrome: Systematic Literature Review to Inform Conceptual Model Design
Sugrue D, van Haalen HG, Rai S, McEwan P. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
Gordon J, McEwan P, Ward T, Penrod JR, Wagner S, Yuan Y. Defining and Estimating the Cure Fraction Bias in Survival Modelling of Novel Immuno-Oncology Therapy Agents in Small-Cell Lung Cancer.
Hill NR, Ayoubkhani D, Lumley M, Lister S, Farooqui U, Clifton D, O'Neil M, McEwan P, Gordon J. Machine Learning to Detect and Diagnose Atrial Fibrillation and Atrial Flutter (AF/F) Using Routine Clinical Data.
Darlington O, Lopes SI, Ward T, Sugrue D, McEwan P, Martin AA, Punekar YS. Estimating Health Outcomes in HIV Infected Patients Treated with a Dual Regimen of Dolutegravir and Rilpivirine in Europe.
Foos V, McEwan P, Lamotte M. Review and Validation of Cardiovascular Risk Prediction Models in East Asian Populations.
Foos V, McEwan P. Conversion of Hypoglycemia Utility Decrements from Categorical Units Reflecting Event History into Event Specific Disutility Scores Applicable to Diabetes Decision Models.
McEwan P, Qin L, Evans ML, Horne L, Palaka E, Grandy S. Associations between serum potassium and clinical outcomes in patients with CKD in a real world setting.
Qin L, McEwan P, Evans ML, Horne, L, Grandy, S. Relationship between Serum Potassium and Dose Modification and Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors in UK Patients with Heart Failure.
Qin L, McEwan P, Evans ML, Palaka E, Grandy S. Relationship between Serum Potassium and Dose Modification and Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors in UK Patients with CKD
Evans M, Qin L, McEwan P, Palaka E, Grandy S. Real World Evidence Characterizing the Association Between serum potassium and clinical outcomes in patients with heart failure
McEwan P, Chubb B, Bennett H. Modelling Cardiovascular Outcomes In Type 2 Diabetes In The ERA Of Cardiovascular Outcomes Trials
Bennett H, Ayoubkhani D, Evans M, McEwan P, Qin L, Grandy S, Palak E. Quantifying The Relationship Between Hyperkalaemia And Outcomes In Patients With Heart Failure Or Chronic Kidney Disease
Bennett H, Palaka E, Ayoubkhani D, Evans M, McEwan P, Bergenheim K, Kim K, Grandy S. A Model To Predict Costs And Outcomes Associated With Hyperkalaemia In Patients With Chronic Kidney Disease Or Heart Failure
Ramos M, McEwan P, Lamotte M, Foos V. The Relationship Of Predicted Benefits In Life Expectancy And Quality Adjusted Life Expectancy For Improved Glucose Control In Type 2 Diabetes Simulation Modeling
Bennett H, Palaka E, Ayoubkhani D, Evans M, Gordon J, Kim K, McEwan P. Impact of End-Stage Renal Disease on Health Economic Outcomes of Hyperkalaemia Management In Patients With Chronic Kidney Disease
Bennett H, McEwan P, Ayoubkhani D, Evans M, Qin L, Kim K, Palaka E. Development Of A Mortality Risk Prediction Tool For Patients With Heart Failure Or Chronic Kidney Disease At Risk Of Hyperkalaemia
Foos V, Lamotte M, Altrabsheh E, Sathananthan A, McEwan P. Determinants Of The Relationship Between Improved Glucose Control And Modeled Health Outcomes In Type 2 Diabetes Simulation Models
Foos V, Lamotte M, Sathananthan A, Altrabsheh E, McEwan P. Exploration Of Run-Time Requirements In Probabilistic Sensitivity Analysis Utilizing A Patient Level Based Type 2 Diabetes Simulation Model
McEWan P, Darlington O, van Doornewaard A, Webster S, Ward T, Martin AA, Punekar YS. Estimating Life Years And Quality-Adjusted Life Years In Heavily Treatment-Experienced (HTE) Patients
Ward T, Gordon J, Bennett Wilton H, Medland S, McEwan P. Contrasting Improving Rates of Cancer Survival In The Context of Life Years Lost Compared To The General Population
Ward T, Gordon J, Wygant G, Yan J, Wang F, McEwan P, Assessing The Economic Impact Of The Introduction Of Daclatasvir In Combination With Asunaprevir For The Treatment Of Chronic Hepatitis C In China
Ward T, Jones B, Harrison JP, Hurst M, Tyas D, McEwan P, Gordon J. The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia
Jones B, Ward T, Harrison JP, Hurst M, Tyas D, McEwan P, Gordon J. The Cost-Effectiveness of Nivolumab for The Treatment of People with Relapsed or Refractory Classical Hodgkin Lymphoma Following Autologous Stem Cell Transplant and Brentuximab Vedotin
McEwan P, Gordon J, Foos V, Lamotte M, Evans M, Paldanius P. Cost Effectiveness Of Type 2 Diabetes Treatments in Middle Eastern Countries: An Economic Evaluation Of The Edge Study Using Patient Level Data
McEwan P, Gordon J, Foos V, Lamotte M, Evans M, Paldanius P. Estimating the cost effectiveness of Vildagliptin versus Sulphonylurea in combination with Metformin: Clinical guidelines versus clinical practice.
McEwan P, Bennett H, O’Reilly K, Robinson P. Contrasting predictions of renal decline between the ADPKD outcomes model and Mayo Clinic imaging classification of ADPKD.
McEwan P, Foos V, Lamotte M, Evans, M. Quantifying the health economic benefit of key therapeutic outcomes in the management of Type 2 diabetes and assessing their inter-relationship
Foos V, Lamotte M, McEwan P. Assessing the impact of simulated time horizon on predicted incremental quality adjusted life years in type 2 Diabetes
Foos V, Lamotte M, McEwan P. Comparing direct and indirect costs of Type 2 Diabetes across three age ranges in the United States
McEwan P, Bennett H, Fellows J, Yapp R, Bergenheim K, Qin L, Varol N, Gordon J. Alternative approaches to modelling HbA1C progression in Type 2 diabetes and their impact on health economic outcomes
Foos V, Lamotte M. McEwan P. The comparison of cardiovascular incidence predictions in Type 1 Diabetes Utilizing alternative risk prediction models
McEwan P, Gordon J, Ward T, Penrod JR, Yuan Y. Empirical Assessment of the impact of model choice (markov State versus partitioned survival) in modelling small-cell lung cancer
McEwan P, Foos V, Lamotte M. Replacing input probability distributions with mean values can bias simulation output: an illustration using the core diabetes model.
McEwan P, Foos V, Lamotte M. Implications of introducing patient heterogeneity in cost effectiveness modelling.
McEwan P, Foos V, Lamotte M. Contrasting model predicted life expectancy in patients with type 2 diabetes across different mortality risk prediction models versus data from the Canadian chronic disease surveillance system
McEwan P, Foos V, Lamotte M. Contrasting predictions of cardiovascular incidence derived from alternative risk prediction models in type 1 diabetes